CAS 2095393-15-8

ARQ 531

CAS: 2095393-15-8

ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.

Formel: C₂₅H₂₃ClN₄O₄

Reinheit: 98.68% - 99.63%

Farbe und Form: Solid

Molekulargewicht: 478.93

Ref: TM-T14323

1,​5-​Anhydro-​2-​[[5-​(2-​chloro-​4-​phenoxybenzoyl)​-​7H-​pyrrolo[2,​3-​d]​pyrimidin-​4-​yl]​amino]​-​2,​3,​4-​trideoxy-​D-​erythro-​hexitol

CAS: 2095393-15-8

Formel: C₂₅H₂₃ClN₄O₄

Reinheit: 99%

Farbe und Form: Solid

Molekulargewicht: 478.9275

Ref: IN-DA01EO8E

ARQ 531

CAS: 2095393-15-8

ARQ 531

Reinheit: ≥98%

Molekulargewicht: 478.93g/mol

Ref: 54-BUP09823

ARQ 531

Kontrolliertes Produkt

CAS: 2095393-15-8

Formel: C₂₅H₂₃ClN₄O₄

Farbe und Form: Neat

Molekulargewicht: 478.928

Ref: TR-A158920

ARQ 531

CAS: 2095393-15-8

ARQ 531 is a small molecule inhibitor specifically designed to target Bruton's tyrosine kinase (BTK), which is a type of enzymatic protein. This compound is meticulously developed within a laboratory setting to disrupt key pathways involved in cancer cell survival. Its mode of action involves the selective and reversible inhibition of BTK, thereby obstructing signal transduction that promotes malignant cell proliferation and survival.

Formel: C₂₅H₂₃ClN₄O₄

Reinheit: Min. 95%

Molekulargewicht: 478.93 g/mol

Ref: 3D-VID39315